Table 6 The GSA result by a network-expanded and cross-species GSA (case example 3)

1

79

10

9.9.E-21

7.5.E-17

Abnormal blood coagulation

2

73

5

1.9.E-09

7.0.E-06

Increased bleeding time

3

37

4

1.3.E-08

3.4.E-05

Gastrointestinal hemorrhage

4

150

5

7.0.E-08

1.2.E-04

Increased leukocyte cell number

5

57

4

7.9.E-08

1.2.E-04

Abnormal cell adhesion

6

1258

9

1.5.E-07

1.9.E-04

Premature death

7

75

4

2.4.E-07

2.6.E-04

Decreased susceptibility to endotoxin shock

8

80

4

3.1.E-07

2.9.E-04

Thrombosis

9

94

4

6.0.E-07

5.0.E-04

Increased monocyte cell number

10

30

3

1.3.E-06

9.1.E-04

Abnormal cellular extravasation

11

277

5

1.4.E-06

9.1.E-04

Hemorrhage

12

3

2

1.5.E-06

9.1.E-04

Purpura

13

33

3

1.7.E-06

1.0.E-03

Decreased susceptibility to bacterial infection induced morbidity/mortality

14

153

4

4.1.E-06

2.1.E-03

Decreased erythrocyte cell number

15

153

4

4.1.E-06

2.1.E-03

Increased neutrophil cell number

16

50

3

6.1.E-06

2.9.E-03

Impaired macrophage chemotaxis

17

51

3

6.5.E-06

2.9.E-03

Decreased platelet aggregation

18

6

2

7.2.E-06

3.0.E-03

Abnormal circulating fibrinogen level

19

7

2

1.0.E-05

3.8.E-03

Uterine hemorrhage

20

7

2

1.0.E-05

3.8.E-03

Petechiae

21

60

3

1.1.E-05

3.8.E-03

Impaired neutrophil recruitment

22

8

2

1.4.E-05

4.4.E-03

Increased susceptibilityto infection induced morbidity/mortality

23

65

3

1.4.E-05

4.4.E-03

Abnormal leukocyte migration

24

211

4

1.5.E-05

4.6.E-03

Increased sensitivityto induced morbidity/mortality

25

69

3

1.6.E-05

4.8.E-03

Increased eosinophil cell number

26

70

3

1.7.E-05

4.8.E-03

Abnormal myelopoiesis

27

9

2

1.7.E-05

4.8.E-03

Hemothorax

28

72

3

1.8.E-05

4.9.E-03

Abnormal cell migration

29

81

3

2.6.E-05

6.4.E-03

Internal hemorrhage

30

11

2

2.6.E-05

6.4.E-03

Skin hemorrhage

31

11

2

2.6.E-05

6.4.E-03

Abnormal platelet aggregation

32

86

3

3.1.E-05

7.3.E-03

Decreased angiogenesis

33

13

2

3.8.E-05

8.5.E-03

Decreased susceptibility to induced choroidal neovascularization

34

100

3

4.9.E-05

1.1.E-02

Abnormal inflammatory response

35

289

4

4.9.E-05

1.1.E-02

Anemia

36

15

2

5.0.E-05

1.1.E-02

Pulmonary alveolar hemorrhage

37

18

2

7.3.E-05

1.5.E-02

Abnormal uterine environment

38

20

2

9.1.E-05

1.8.E-02

Abnormal physiological neovascularization

39

21

2

1.0.E-04

1.9.E-02

Hemoperitoneum

40

22

2

1.1.E-04

2.0.E-02

Pregnancy-related premature death

41

22

2

1.1.E-04

2.0.E-02

Abnormal platelet activation

42

133

3

1.1.E-04

2.0.E-02

Decreased platelet cell number

43

24

2

1.3.E-04

2.3.E-02

Increased susceptibility to fungal infection

44

33

2

2.5.E-04

4.3.E-02

Decreased cerebral infarction size

45

180

3

2.7.E-04

4.6.E-02

Pallor